证券代码：002693 证券简称：双成药业 公告编号：2023-043 海南双成药业股份有限公司 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "海南辖区投资者网上集体接待日暨上市公司业绩说明会"活动，活动时间为 2023 年 5 月 26 日 14:30-17:00，平台登陆地址为：http://rs.p5w.net。 届时，海南双成药业股份有限公司主要高管人员将参加本次活动，通过网络 在线交流形式，就公司 2022 年年报披露、财务数据、公司治理、内部控制、发 展战略、经营状况、现金分红、重大事项、可持续发展等投资者所关心的问题， 与投资者进行"一对多"形式的沟通与交流。欢迎广大投资者踊跃参与。 特此公告。 2023 年 5 月 17 日 关于参加"2022 年度海南辖区上市公司业绩说明会"的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司董事会 ...

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司 投资者关系活动记录表 编号：2023-01 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2022年度网上业绩说明会的全体投资者 | | 时间 | 2023年05月15日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/） | | 上市公司接待人员姓名 | 董事、总经理 Jianming Li | | | 独立董事 肖建华 | | | 副总经理、董事会秘书 于晓风 | | | 财务总监 王旭光 | | | 1 .23年第一季度公司表现亮眼，第二季度经营情况如何？ | | | 答:尊敬的投资者，您好。第二季度经营正常，具体情况请关注 | | 投资者关系活动主要内容 | 公司半年报。营业收入与市场变化有关，具有波动性，请注意投资 | | 介绍 | 风险。 | | ...

Financial Performance - The company's revenue for Q1 2023 was ¥81,485,154.92, representing an increase of 11.27% compared to ¥73,230,987.79 in the same period last year[2] - Net profit attributable to shareholders reached ¥4,505,619.82, a significant increase of 517.11% from ¥730,119.24 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥1,599,812.27, up 125.66% from a loss of ¥6,233,934.62 in the previous year[2] - Basic earnings per share increased to ¥0.0110, reflecting a growth of 511.11% compared to ¥0.0018 in the same period last year[2] - Total operating revenue for Q1 2023 was CNY 81,485,154.92, an increase of 11.5% compared to CNY 73,230,987.79 in the same period last year[31] - Net profit for Q1 2023 was CNY 103,484.98, a significant recovery from a net loss of CNY 2,492,564.24 in the previous year[32] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0110, compared to CNY 0.0018 in the same period last year, representing a growth of 511.1%[32] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥19,881,051.09, a decline of 30.07% compared to -¥15,284,942.57 in the same period last year[2] - The company reported a decrease in cash and cash equivalents from RMB 12,196,777.95 at the beginning of the year to RMB 5,920,315.43 at the end of the quarter[26] - The company's total current assets decreased from RMB 252,394,374.44 at the beginning of the year to RMB 241,151,591.67 at the end of the quarter[28] - The total cash and cash equivalents at the end of the period were 5,920,315.43 CNY, down from 14,375,610.63 CNY in the previous period, indicating a decrease in liquidity[34] - The total cash outflow from operating activities was 100,818,167.95 CNY, compared to 95,615,637.78 CNY in the previous period, indicating higher operational costs[33] Investment and Financing Activities - The company reported a 129.10% increase in cash received from investment recoveries, indicating improved cash flow management[9] - Total cash inflow from investment activities was 150,408,649.83 CNY, significantly higher than 63,667,129.39 CNY in the previous period, reflecting increased investment recovery[34] - The net cash flow from investment activities improved to 20,985,778.54 CNY, compared to -41,225,949.49 CNY in the previous period, showing a positive turnaround[34] - Cash inflow from financing activities decreased to 4,392,700.00 CNY from 51,708,400.00 CNY in the previous period, indicating reduced borrowing[34] - The net cash flow from financing activities was -1,979,509.71 CNY, a significant drop from 49,291,851.39 CNY in the previous period, highlighting challenges in financing[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥890,784,444.32, a decrease of 2.22% from ¥911,018,789.08 at the end of the previous year[2] - The company's total liabilities decreased to CNY 309,027,615.64 from CNY 330,076,360.29 at the beginning of the year, a reduction of approximately 6.4%[30] - The total equity attributable to shareholders of the parent company increased to CNY 518,764,494.90 from CNY 513,547,960.18, marking a growth of 1.4%[30] - The company's total non-current assets decreased from RMB 658,624,414.64 at the beginning of the year to RMB 649,632,852.65 at the end of the quarter[28] Research and Development - Research and development expenses grew by 46.39% year-on-year, indicating increased investment in R&D projects[7] - Research and development expenses rose to CNY 2,589,268.35, up 46.5% from CNY 1,768,762.68 in the previous year[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,474[11] - Hainan Shuangcheng Investment Co., Ltd. holds 32.92% of shares, with 136,516,546 shares pledged[11] - HSP Investment Holdings Limited owns 15.58% of shares, totaling 64,599,379 shares, with 16,210,000 shares pledged[11] - The top ten shareholders include both domestic and foreign entities, with significant shareholding by Hainan Shuangcheng Investment Co., Ltd. and HSP Investment Holdings Limited[11] - The company has implemented a stock option and restricted stock incentive plan, granting 7 million restricted shares at RMB 1.91 per share and 7 million stock options at RMB 3.82 per option[13] Strategic Agreements - The company signed a product rights transfer agreement with Chongqing Laimei Pharmaceutical Co., Ltd. and Hangzhou Boying Health Technology Co., Ltd. for a total contract amount of RMB 32 million, acquiring all tangible and intangible assets related to the acetate triptorelin injection in China[20] - The company entered into a licensing and supply agreement with Meitheal Pharmaceuticals, Inc. and Hong Kong King-Friend Industrial Co., Ltd. for the exclusive rights to develop and produce paclitaxel injection (albumin-bound) in the U.S., with a total milestone payment of USD 6 million, of which USD 3 million has been received[23] Employee Compensation and Incentives - The company reported a decrease in employee compensation payable from CNY 8,596,015.63 to CNY 5,860,557.02, a decline of 31.5%[30] - The company’s incentive plan aligns with its strategic goals to enhance employee motivation and retention[19] Audit and Reliability - The first quarter report was not audited, which may affect the reliability of the financial data presented[35] - The company did not report any new product launches or technological advancements during this quarter[36]

证券代码：002693 证券简称：双成药业 公告编号：2023-035 海南双成药业股份有限公司 会议召开时间：2023 年 5 月 15 日（星期一）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日在 巨潮资讯网上披露了《2022 年年度报告》及其摘要。为便于广大投资者更加全 面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 5 月 15 日（星 期一）15:00-17:00 在"价值在线"（www.ir-online.cn）举办海南双成药业股 份有限公司 2022 年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投 资者的意见和建议。 一、说明会召开的时间、地点和方式 四、联系人及咨询办法 联系人：双成药业证券部 电话：0898-68592978 邮箱：lifen@shuangchengmed.com ...

Financial Performance - The company's operating revenue for 2022 was ¥274,754,114.70, a decrease of 14.22% compared to ¥320,293,514.52 in 2021[21] - The net profit attributable to shareholders in 2022 was ¥9,012,396.69, representing a significant increase of 144.34% from a loss of ¥20,325,073.94 in 2021[21] - The net cash flow from operating activities was ¥25,217,762.02, an increase of 7.07% compared to ¥23,553,573.54 in the previous year[21] - The total assets at the end of 2022 amounted to ¥911,018,789.08, reflecting a growth of 6.61% from ¥854,556,164.94 at the end of 2021[21] - The net assets attributable to shareholders increased by 6.58% to ¥513,547,960.18 at the end of 2022, up from ¥481,848,410.05 in 2021[21] - The basic earnings per share for 2022 was ¥0.02, a turnaround from a loss of ¥0.05 per share in 2021, marking a 140.00% improvement[21] - The weighted average return on net assets was 1.80% in 2022, an increase of 6.01 percentage points from -4.21% in 2021[21] - The company reported a net profit excluding non-recurring gains and losses of -¥36,881,064.99 in 2022, a slight improvement of 6.35% from -¥39,383,459.22 in 2021[21] Revenue and Profit Trends - The company's total revenue for Q1 2022 was ¥73,230,987.79, which decreased to ¥53,583,090.97 in Q2, then increased to ¥71,049,140.92 in Q3, and reached ¥76,890,895.02 in Q4[23] - The net profit attributable to shareholders was ¥730,119.24 in Q1, but turned negative in Q2 and Q3 with losses of ¥2,543,950.58 and ¥1,806,463.72 respectively, before recovering to ¥12,632,691.75 in Q4[23] - Non-operating income for 2022 totaled ¥45,893,461.68, significantly higher than ¥19,058,385.28 in 2021, driven by gains from asset disposals and government subsidies[23] Industry Context - The pharmaceutical industry in China saw a revenue decline of 1.6% in 2022, with total revenue of ¥2,911.14 billion and a profit drop of 31.8% to ¥428.87 billion[28] - The government health expenditure in 2021 was ¥2,075.18 billion, accounting for 27.4% of total health spending, indicating a strong reliance on public funding in the healthcare sector[28] R&D and Innovation - The company is focusing on innovation and collaboration with small and medium enterprises to enhance competitiveness and resilience in the supply chain[29] - The company has developed multiple peptide drugs and 20 other therapeutic drugs, with significant international approvals including from the FDA and EMA[39] - The company focuses on the research and development of peptide products, with nearly 10 new peptide products in various stages of approval and development[42] - The company received FDA approval for the injection of Eptifibatide (75mg/100mL) and registration for Acetate Triptorelin injection (1ml:0.1mg)[49] Market Strategy - The company plans to enhance its R&D capabilities, focusing on the development of peptide raw materials and formulations, while increasing R&D investment and stabilizing the R&D team[85] - The company aims to expand its market presence through international collaborations, including patent licensing and joint development, to introduce advanced drug technologies into the domestic market[85] - The company plans to accelerate the submission of DMF and ANDA applications in the US and EU to enhance internationalization[47] Financial Management - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company reported a significant decline in investment income, down 52.81% to ¥4,689,841.85, primarily due to reduced financial investment returns[69] - The total net increase in cash and cash equivalents was -¥14,820,845.53, a decline of 193.68% compared to the previous year[66] Risk Factors - The company faces various risks including industry policy changes, drug price reductions, and financial risks, which are detailed in the report[5] - The company is exposed to financial risks from foreign exchange fluctuations and increasing accounts receivable and inventory, which may pressure operational funds[95] - The company is addressing the risk of drug price declines due to national policies by enhancing product quality and seizing market opportunities[94] Corporate Governance - The company emphasized its commitment to improving corporate governance and compliance with regulatory requirements, having held 3 shareholder meetings during the reporting period[101] - The board of directors held 13 meetings, ensuring diligent oversight and independent opinions on significant matters[103] - The company has established a fair and transparent performance evaluation system for directors and senior management, enhancing team cohesion and operational efficiency[104] Environmental Responsibility - The company has established a comprehensive pollution management system to comply with environmental regulations and reduce environmental risks associated with production[93] - The company invested over 4.84 million RMB in environmental protection facilities and daily expenses, focusing on construction, operation, maintenance, and testing of environmental protection equipment[168] - The company has not faced any administrative penalties due to environmental issues during the reporting period[168] Shareholder Relations - The company confirmed that it operates independently from its controlling shareholder, maintaining autonomy in business operations and decision-making[102] - The company has a clear asset ownership structure, with complete control over its production and operational facilities, ensuring no asset misappropriation by controlling shareholders[109] - The company has committed to a cash dividend distribution policy, aiming for a cumulative cash distribution of at least 30% of the average distributable profit over the past three years from 2021 to 2023[178]

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司投资者关系活动记录表 编号：014-20150325 | --- | --- | --- | |----------------|-------------------------|----------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 兴业证券 孙晓东 | | | 人员姓名 | | | | 时间 | 2015 年 3 月 25 | 日（星期三）上午 10:00 | | 地点 | 公司 | | | 上市公司接待人 | 董事会秘书 于晓风 | | | 员姓名 | | | | 投资者关系活动 | 1 | 、请介绍公司国际化发展战略。 | | 主要内容介绍 | 公司自 2008 | 年起就开始推动国际化，一直致力于用国际 | | --- | - ...

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司投资者关系活动记录表 编号：013-20150305 | --- | --- | --- | |----------------|------------------------|-----------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 东方证券 田加强 | | | 人员姓名 | 国投瑞银 张佳荣 | | | 时间 | 2015 年 3 月 5 | 日（星期四）下午 13:30 | | 地点 | 公司 | | | 上市公司接待人 | 董事会秘书 于晓风 | | | 员姓名 | | | | 投资者关系活动 | 1 | 、请介绍非公开发行股票事项的进展情况。 | | 主要内容介绍 | 公司股东大会已于 | 3 月 3 日审议通过了非公开发行股 ...

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司投资者关系活动记录表 编号：015-20200611 | --- | --- | --- | |----------------|-------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 东方光石（北京）实业有限公司刘佳鹏、刘子瑜、姜晚晴 | | 人员姓名 | | | | 时间 | 2020 年 6 月 11 | 日（星期四）下午 15:00 | | 地点 | 公司 | | | 上市公司接待人 | 董事会秘书 于晓风 | | | 员姓名 | 证券事务代表 李芬 | | | 投资者关系活动 | | 1、多肽产品在疫情期间销量情况及公司销售情况。 | | 主要内容介 ...

证券代码：002693 证券简称：双成药业 编号：017-20210524 | --- | --- | --- | --- | |-------------------------|-------------------------------------------------|----------------------------|-------------------------------------------------------------| | | | | | | | □ 特定对象调研 | □ 分析师会议 | | | 投资者关系活动 | □ 媒体采访 √ | 业绩说明会 | | | 类别 | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 通过全景网"投资者关系互动平台"（ 南辖区上市公司 | | http://ir.p5w.net ）参与"海 年度业绩网上集体说明会"的投资者 | | | 2020 | | | | 时间 | 2021 年 5 月 24 日 | 15:30 ...

2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 海南双成药业股份有限公司 2022 年第三季度报告 证券代码：002693 证券简称：双成药业 公告编号：2022-083 海南双成药业股份有限公司 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 71,049,140.92 | -7.92% | 197,863,219.68 | -21.11% | | 归属于上市公司股东的净 利润（元） | -1,806,463.72 | 81.99% | -3,620,295.06 | 10.25% | | 归属于上市公司股东的扣 除非经常性损益的净利润 | -3,536,035.47 | 67.69% | -23,560,109.61 | -10.77% | | ...